CAR-T: What’s next? Part 2
In my previous blog post, I suggested that the market size for gene-modified T-cell therapies would be roughly $9 Bn in 10 years, with a...
Pharmacy Benefit Managers (PBMs): Bending the cost curve in the wrong direction
In the NY Times article, “Take the Generic, Patients Are Told. Until They Are Not.”, Pharmacy Benefit Managers (PBMs) were called out for...
